Prospective Study
Copyright ©The Author(s) 2015.
World J Gastroenterol. Aug 14, 2015; 21(30): 9163-9174
Published online Aug 14, 2015. doi: 10.3748/wjg.v21.i30.9163
Table 1 Group of patients according to hepatitis C virus treatment history n (%)
All patientsBOCTVRP valueFibrosisNon-F4F4P value
(n = 1057) (100)(n = 405) (38)(n = 652) (62)All patients(n = 423) (44)(n = 545) (56)
(n = 958) (100)
TN319 (30)130 (32)189 (29)0.000294 (30)129 (31)165 (30)0.010
TE738 (70)275 (68)463 (71)664 (70)294 (67)380 (70)
R298 (28)77 (19)221 (34)270 (28)138 (33)132 (24)
PR123 (12)55 (14)68 (10)113 (12)44 (10)69 (13)
NR260 (25)119 (29)141 (22)238 (25)86 (20)152 (28)
Unknown responders57 (5)24 (6)33 (5)53 (6)26 (6)27 (5)

  • Citation: Salmerón J, Vinaixa C, Berenguer R, Pascasio JM, Sánchez Ruano JJ, Serra M&, Gila A, Diago M, Romero-Gómez M, Navarro JM, Testillano M, Fernández C, Espinosa D, Carmona I, Pons JA, Jorquera F, Rodriguez FJ, Pérez R, Montero JL, Granados R, Fernández M, Martín AB, Muñoz de Rueda P, Quiles R, Alhambra Spanish Study Group. Effectiveness and safety of first-generation protease inhibitors in clinical practice: Hepatitis C virus patients with advanced fibrosis. World J Gastroenterol 2015; 21(30): 9163-9174
  • URL: https://www.wjgnet.com/1007-9327/full/v21/i30/9163.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v21.i30.9163